Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Abstract

Individuals with MASLD and elevated liver enzyme levels exhibited significantly higher risks of all-cause and cardiometabolic deaths and should be monitored and given consultation on cardiometabolic modifications.